Morgan Stanley raised the firm’s price target on Amgen (AMGN) to $309 from $304 and keeps an Equal Weight rating on the shares after the company posted a Q4 beat and gave 2026 guidance that bracketed consensus.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen price target raised to $345 from $315 at Citi
- Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating
- Closing Bell Movers: AMD down 8% on earnings despite beat
- Amgen reports Q4 adjusted EPS $5.29, consensus $4.76
- Amgen sees FY26 adjusted EPS $21.60-$23.00, consensus $22.14